Olverembatinib plus immunotherapy versus olverembatinib plus allogeneic hematopoietic cell transplantation in adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia

Blood Cancer Journal 2026 Open access

Read full text
Authors: Chenying Li, Hongyan Tong, Huafeng Wang, Yanling Ren, Jiejing Qian, Xinping Zhou, Gaixiang Xu, Liangshun You, Liping Mao, Haitao Meng, Wenjuan Yu, Xingnong Ye
+6 more Min Yang, Jian Huang, De Zhou, Wanzhuo Xie, Jie Jin, Yinjun Lou
DOI: 10.1038/s41408-026-01591-y
Cited by: 1
References: 13

Abstract

Philadelphia chromosome–positive (Ph⁺) acute lymphoblastic leukemia (ALL) accounts for approximately 20–30% of adult B-cell ALL cases [ 1 ]. Historically, Ph⁺ ALL has been associated with poor outcomes due to intrinsic chemoresistance. The integration of BCR::ABL1 tyrosine kinase inhibitors (TKIs) into frontline induction regimens has dramatically improved complete remission (CR) rates to >95%. Allogeneic hematopoietic cell transplantation (allo-HSCT) remains the standard consolidation strategy for patients in first CR [ 2 ].

Fields of Study & Subjects

Chronic Myeloid Leukemia Treatments Acute Lymphoblastic Leukemia research Lung Cancer Treatments and Mutations

Publication details

Journal / source
Blood Cancer Journal
Publisher
Springer Science and Business Media LLC
Volume
16
Issue
1
Publication date
27 July 2026
Language
EN